Human cancers are the sole focus of research at CHRISTUS Stehlin Foundation. With this unique emphasis, the Foundation develops new investigational drugs and novel therapies that improve the prognoses for thousands of cancer patients.
Under the direction of the Foundation’s renowned laboratory director, Dr. Beppino Giovanella, discoveries in the lab are translated to point-of-care patient applications. Stehlin’s potent anticancer drug CZ48 currently is in Phase I human trials, a long and expensive process to determine the drug’s safety and efficacy in human cancer patients. Learn more about CZ48 and other Current Research Projects.
CZ48 is among the latest in a long history of Foundation innovations and breakthroughs. Stehlin researchers were instrumental in the development of Herceptin®, a drug widely-used in the fight against breast cancer. Dr. Giovanella pioneered the development and use of the immuno-suppressed “nude” mouse in cancer research. Stehlin scientists demonstrated the selective sensitivity of cancer cells to heat, and Dr. Stehlin pioneered the combination of heat and chemotherapy (hyperthermic perfusion) to treat patients with advanced melanomas of the arms and legs. Learn more about Foundation Achievements.
In 2011, the work of the dedicated Stehlin researchers was rewarded with the Foundation’s move to a state-of-the-art 27,000 square foot facility with 11 separate research laboratories. The facility almost doubles the space dedicated to research and boasts the latest equipment and technologies. Learn more about the Laboratory.
With the support and involvement of generous individuals, private foundations, and corporate partners, Stehlin researchers continue leading the fight to find a cure.
“I think it has been too easy to overlook what a progressive physician Dr. John Stehlin was, and how pivotal he was for the humane treatment of individuals with cancer. He changed the cancer landscape forever, and his work continues with the research the CHRISTUS Stehlin Foundation is doing today.”
Dr. Peter de Ipolyi,
CHRISTUS Stehlin Foundation for Cancer Research will join CHRISTUS St. Catherine and CHRISTUS St. John in a new partnership with Houston Methodist.
There are currently 13.7 million cancer survivors in the United States and the number is expected to rise by 31 percent to 18 million by 2022, according to a new report. >> Click article title for more.
A new study suggests that sometimes simply watching and waiting is a safe alternative to surgery for older patients with small kidney tumors. A surgical oncologist said that the findings, "should allow clinicians and patients to feel more comfortable about surveillance, particularly for the 'oldest old' and those patients with multiple [other health conditions] that would make surgery especially high risk." >> Click on article title for more.
American women who smoke have a dramatically increased risk of death from lung cancer and chronic obstructive pulmonary disease than they did 20 years ago. Compared to women who never smoked, a female smoker's risk of death from lung cancer is almost 26 times higher now. In the 1960s a female smoker's risk of death was only three times higher than a female nonsmoker's, according to new research. >> Click on title to read more